 BASEL, Switzerland--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Swissmedic has accepted the marketing authorization application MAA for BRUKINSA, a treatment option for adult patients with Waldenströms macroglobulinaemia WM. Swissmedic has started the formal review of the MAA. BRUKINSA has already been granted orphan drug status by Swissmedic. Swissmedic, 